{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-018790","form_type":"8-K","ticker":"CRSP","cik":"0001674416","company_name":"CRISPR Therapeutics AG","filed_at":"2023-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.979492+00:00","generated_at":"2026-06-15T13:35:28.393665+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"CRISPR Therapeutics reports Q1 net loss of $53.1M; exa-cel submissions complete in US, EU, UK","bullets":["Revenue of $100.0M from Vertex upfront; net loss improved to $53.1M vs $179.2M in Q1 2022.","Cash and securities $1,889.5M; R&D expenses $99.9M, G&A $22.4M.","Completed rolling BLAs for exa-cel in SCD and TDT; EMA and MHRA submissions validated.","Initiated clinical trials for next-gen CAR T candidates CTX112 (CD19) and CTX131 (CD70).","Appointed Raju Prasad as CFO; Brad Bolzon left board; Vertex deal includes $100M upfront and up to $230M milestones."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-018790","json":"https://secwatch.observer/filing/0000950170-23-018790.json","markdown":"https://secwatch.observer/filing/0000950170-23-018790.md","text":"https://secwatch.observer/filing/0000950170-23-018790.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1674416/000095017023018790/0000950170-23-018790-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1674416/000095017023018790/crsp-20230508.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T13:35:28.393665+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"41924b66763b69eb1fc2544265c87e8f23640d9f","claim":"CRISPR Therapeutics AG reported financial results for first quarter ended March 31, 2023.","evidence_excerpt":"CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today reported financial results for the first quarter ended March 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1674416/000095017023018790/0000950170-23-018790-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}